Skip to main content
Premium Trial:

Request an Annual Quote

Caris Life Sciences, Ono Pharmaceutical Ink Cancer Drug Development Collaboration

NEW YORK – Caris Life Sciences and Ono Pharmaceutical said Thursday that they have entered a strategic collaboration using Caris' molecular profiling technologies across several studies of investigational targeted and immune-based cancer therapies.

Under the terms of the agreement, Caris will provide its suite of next-generation sequencing services, including its comprehensive liquid biopsy assay, which assesses 22,000 genes in both DNA and RNA, to aid in the development of therapies in areas of unmet need.

According to the Osaka, Japan-based pharma firm, the collaboration will start with one initial Phase III trial, with additional targets to be determined later.

"Collaborating with Caris gives us the opportunity to utilize world-class advanced technologies to improve our novel drug development capabilities," Kiyoaki Idemitsu, executive officer and executive director of clinical development at Ono, said in a statement.

Financial terms of the deal were not disclosed.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.